Neurogene stock surges 30% on FDA breakthrough therapy status

Neurogene Inc. (NASDAQ: NGNE) saw its shares surge by 30% in after-hours trading on Thursday, February 26, 2026, following the announcement that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to its investigational gene therapy, NGN-401. This significant regulatory milestone was awarded for the treatment of Rett syndrome, a severe rare genetic disorder that affects brain development. The catalyst for the stock’s sharp increase was the FDA’s decision, which was based on interim efficacy and safety data indicating that the therapy offers substantial improvement over currently available options for this serious condition. NGN-401 is designed as a one-time treatment employing Neurogene’s proprietary EXACT transgene regulation technology to deliver the full-length human MECP2 gene. The therapy is administered via intracerebroventricular delivery, a method that allows for the direct targeting of the brain and nervous system. The designation was supported by clinical data from the Phase 1/2 trial recorded as of October 30, 2025, which demonstrated clinically meaningful and durable functional improvements across multiple Rett syndrome domains. Notably, the data evidenced continued skill acquisition over time, suggesting a sustained therapeutic benefit for patients suffering from the debilitating disease. The Breakthrough Therapy designation provides Neurogene with several strategic advantages intended to expedite the drug's development and review process. These benefits include eligibility for Priority Review, the ability to utilize rolling submissions for the Biologics License Application (BLA), and enhanced organizational commitment from the FDA to determine an efficient route to approval. Neurogene is currently evaluating NGN-401 in the Embolden registrational clinical trial and expects to complete dosing in the second quarter of 2026, with plans to present additional interim Phase 1/2 data in mid-2026. The therapy has previously received multiple regulatory designations, including Regenerative Medicine Advanced Therapy and Rare Pediatric Disease designations, and was selected for the FDA’s Support for Clinical Trials Advancing Rare Disease Therapeutics Pilot Program.